Description: Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Home Page: www.humacyte.com
HUMA Technical Analysis
2525 East North Carolina Highway 54
Durham,
NC
27713
United States
Phone:
919 313 9633
Officers
| Name | Title |
|---|---|
| Dr. Laura E. Niklason M.D., Ph.D. | Founder, Pres, CEO & Director |
| Mr. Dale A. Sander | CFO, Chief Corp. Devel. Officer & Treasurer |
| Dr. Heather Ledbetter Prichard Ph.D. | Chief Operating Officer |
| Dr. Juliana L. Blum Ph.D. | Co-Founder & Exec. VP of Corp. Devel. |
| Ms. Sabrina Osborne | Exec. VP of Bus. Strategy & People |
| Mr. William John Scheessele | Chief Commercial Officer |
| Dr. Shamik J. Parikh M.D. | Chief Medical Officer |
| Mr. Harold Alterson | Sr. VP of Quality |
| Dr. Yang Cao M.D., Ph.D. | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.7468 |
| Price-to-Book MRQ: | 2.3983 |
| Price-to-Sales TTM: | 153.9075 |
| IPO Date: | 2021-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 145 |